Genetic Screening of a Large Series of North American Sporadic and Familial Frontotemporal Dementia Cases

Introduction: The Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) consortia are two closely connected studies, involving multiple North American centers that evaluate both sporadic and familial frontotemporal dementia (FTD) participants and study longitudinal changes.

Methods: We screened the major dementia-associated genes in 302 sporadic and 390 familial (symptomatic or at-risk) participants enrolled in these studies.

Results: Among the sporadic patients, 16 (5.3%) carried chromosome 9 open reading frame 72 (C9orf72), microtubule-associated protein tau (MAPT), and progranulin (GRN) pathogenic variants, whereas in the familial series we identified 207 carriers from 146 families. Of interest, one patient was found to carry a homozygous C9orf72 expansion, while another carried both a C9orf72 expansion and a GRN pathogenic variant. We also identified likely pathogenic variants in the TAR DNA binding protein (TARDBP), presenilin 1 (PSEN1), and valosin containing protein (VCP) genes, and a subset of variants of unknown significance in other rare FTD genes.

Discussion: Our study reports the genetic characterization of a large FTD series and supports an unbiased sequencing screen, irrespective of clinical presentation or family history.

Citing Articles

Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders.

Sheth U, Oijerstedt L, Heckman M, White L, Heuer H, Lario Lago A Mol Neurodegener. 2025; 20(1):30.

PMID: 40075459 PMC: 11905702. DOI: 10.1186/s13024-025-00821-4.

Clinical and neuropathological associations of plasma Aβ/Aβ, p-tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders.

Rajbanshi B, Prufer Q C Araujo I, VandeVrede L, Ljubenkov P, Staffaroni A, Heuer H Alzheimers Dement (Amst). 2025; 17(1):e70078.

PMID: 39886325 PMC: 11780117. DOI: 10.1002/dad2.70078.

Brain aging rejuvenation factors in adults with genetic and sporadic neurodegenerative disease.

Casaletto K, Saloner R, Kornak J, Staffaroni A, Villeda S, Paolillo E Brain Commun. 2025; 7(1):fcae432.

PMID: 39816189 PMC: 11734525. DOI: 10.1093/braincomms/fcae432.

Psychotropic medication usage in sporadic versus genetic behavioral-variant frontotemporal dementia.

Vargas-Gonzalez J, Dimal N, Cortez K, Heuer H, Forsberg L, Appleby B Alzheimers Dement. 2024; 21(2):e14448.

PMID: 39713899 PMC: 11848424. DOI: 10.1002/alz.14448.

Gene-Specific Effects on Brain Volume and Cognition of in Frontotemporal Lobar Degeneration.

Vandebergh M, Ramos E, Corriveau-Lecavalier N, Ramanan V, Kornak J, Mester C Neurology. 2024; 103(8):e209832.

PMID: 39321401 PMC: 11424506. DOI: 10.1212/WNL.0000000000209832.

References

Renton A, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs J . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011; 72(2):257-68. PMC: 3200438. DOI: 10.1016/j.neuron.2011.09.010. View

Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion C, Couratier P . TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol. 2009; 65(4):470-3. DOI: 10.1002/ana.21612. View

van Blitterswijk M, Baker M, DeJesus-Hernandez M, Ghidoni R, Benussi L, Finger E . C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology. 2013; 81(15):1332-41. PMC: 3806926. DOI: 10.1212/WNL.0b013e3182a8250c. View

Tresse E, Salomons F, Vesa J, Bott L, Kimonis V, Yao T . VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. Autophagy. 2010; 6(2):217-27. PMC: 2929010. DOI: 10.4161/auto.6.2.11014. View

Robles A, Sobrido M, Garcia-Murias M, Prieto J, Lema M, Santos D . Clinical picture of a patient with a novel PSEN1 mutation (L424V). Am J Alzheimers Dis Other Demen. 2008; 24(1):40-5. PMC: 10846114. DOI: 10.1177/1533317508324272. View

Van Langenhove T, van der Zee J, Sleegers K, Engelborghs S, Vandenberghe R, Gijselinck I . Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology. 2010; 74(5):366-71. DOI: 10.1212/WNL.0b013e3181ccc732. View

Wang K, Li M, Hakonarson H . ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164. PMC: 2938201. DOI: 10.1093/nar/gkq603. View

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, Murray M, Heckman M, Diehl N . Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 2013; 12(10):978-88. PMC: 3879782. DOI: 10.1016/S1474-4422(13)70210-2. View

10.

Chi S, Jiang T, Tan L, Yu J . Distinct neurological disorders with C9orf72 mutations: genetics, pathogenesis, and therapy. Neurosci Biobehav Rev. 2016; 66:127-42. DOI: 10.1016/j.neubiorev.2016.03.033. View

11.

Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E . TREM2 variants in Alzheimer's disease. N Engl J Med. 2012; 368(2):117-27. PMC: 3631573. DOI: 10.1056/NEJMoa1211851. View

12.

Ossenkoppele R, Pijnenburg Y, Perry D, Cohn-Sheehy B, Scheltens N, Vogel J . The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain. 2015; 138(Pt 9):2732-49. PMC: 4623840. DOI: 10.1093/brain/awv191. View

13.

Bernardi L, Tomaino C, Anfossi M, Gallo M, Geracitano S, Costanzo A . Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. Neurobiol Aging. 2008; 30(11):1825-33. DOI: 10.1016/j.neurobiolaging.2008.01.005. View

14.

Goldman J, Van Deerlin V . Alzheimer's Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing. Mol Diagn Ther. 2018; 22(5):505-513. PMC: 6472481. DOI: 10.1007/s40291-018-0347-7. View

15.

McLaren W, Gil L, Hunt S, Riat H, Ritchie G, Thormann A . The Ensembl Variant Effect Predictor. Genome Biol. 2016; 17(1):122. PMC: 4893825. DOI: 10.1186/s13059-016-0974-4. View

16.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

17.

Majounie E, Renton A, Mok K, Dopper E, Waite A, Rollinson S . Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012; 11(4):323-30. PMC: 3322422. DOI: 10.1016/S1474-4422(12)70043-1. View

18.

Murray M, DeJesus-Hernandez M, Rutherford N, Baker M, Duara R, Graff-Radford N . Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 2011; 122(6):673-90. PMC: 3277860. DOI: 10.1007/s00401-011-0907-y. View

19.

Fratta P, Poulter M, Lashley T, Rohrer J, Polke J, Beck J . Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol. 2013; 126(3):401-9. PMC: 3753468. DOI: 10.1007/s00401-013-1147-0. View

20.

Ticozzi N, Leclerc A, van Blitterswijk M, Keagle P, McKenna-Yasek D, Sapp P . Mutational analysis of TARDBP in neurodegenerative diseases. Neurobiol Aging. 2009; 32(11):2096-9. PMC: 2889148. DOI: 10.1016/j.neurobiolaging.2009.11.018. View